Human papillomavirus prevalence, genotype distribution, and prognostic factors of vaginal cancer
Open Access
- 24 July 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (11) , 1996-2008
Abstract
We aimed to investigate human papillomavirus (HPV) prevalence and genotype distribution and prognostic factors in vaginal cancer (VC). VC patients who received treatment between 1989 and 2020 were retrospectively reviewed. L1 general polymerase chain reaction (PCR) followed by HPV Blot (King Car, I‐Lan, Taiwan) and E6 type‐specific‐PCR were performed for genotyping firstly. P16 and p53 immunohistochemistry staining was performed. Univariate and multivariate analyses identified predictors of clinical outcomes.79 VC patients were eligible for analysis. 73 patients (92.4%) were squamous cell carcinoma (SCC) and 6 (7.6%) as non‐SCC. The median follow‐up time was 134.3 months (range 0.9–273.4). Among nine initially HPV‐negative cases, seven were identified as being positive through HPV16/18/45/52/58 whole‐genome amplification followed by Sanger sequencing (WGASS). HPV DNA sequences were detected in 98.6% of SCC and 83.3% of non‐SCC, respectively, with HPV16 (49.4%), HPV52 (15.2%) and HPV58 (8.9%) being predominant. Patients with paraaortic lymph node (LN) metastasis had a 5‐year cancer‐specific survival (CSS) rate of 0%. Multivariate analysis revealed that only p16 and stage were significantly correlated with prognosis. Variables with strong correlations (p16‐ and HPV‐positivity, LN metastasis and stage), were included in models 2–5 alternatively. Stage III/IV (hazard ratio [HR] = 3.64–4.56) and LN metastasis (HR = 2.81–3.44) were significant negative predictors of CSS, whereas p16‐positivity (HR = 0.29–0.32) and HPV‐positivity (HR = 0.14) were related to better prognosis. In conclusion, 97.5% of VCs were HPV‐positive with WGASS. Stage III/IV and LN metastasis were significant negative predictors, whereas p16‐ and HPV‐positivity were significantly associated with better prognosis.Keywords
Funding Information
- Ministry of Health and Welfare (MOHW109‐TDU‐B‐212‐114005, MOHW110‐TDU‐B‐212‐114005, MOHW111‐TDU‐B‐212‐114005)
- Chang Gung Medical Foundation (CMRPG3L0591, CMRPG3L0701/2)
This publication has 30 references indexed in Scilit:
- Cancer of the vagina: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- Current update on vaginal malignanciesAbdominal Radiology, 2021
- Role of human papillomavirus status after conization for high‐grade cervical intraepithelial neoplasiaInternational Journal of Cancer, 2020
- Revised FIGO staging for carcinoma of the cervix uteriInternational Journal of Gynecology & Obstetrics, 2019
- Cancer of the vaginaInternational Journal of Gynecology & Obstetrics, 2018
- Vaginal cancerCritical Reviews in Oncology/Hematology, 2012
- Human papillomavirus in vaginal intraepithelial neoplasiaInternational Journal of Cancer, 2011
- Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysisInternational Journal of Cancer, 2009
- Human papillomavirus genotype in cervical cancer: A population‐based studyInternational Journal of Cancer, 2007
- A Population-Based Study of Squamous Cell Vaginal Cancer: HPV and CofactorsGynecologic Oncology, 2002